290298-12-3

Usage

Uses

Used in Pharmaceutical Industry:
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate is used as a potential pharmaceutical compound for its diverse functional groups and complex structure, which may contribute to its efficacy in treating various medical conditions.
Used in Chemical Industry:
In the chemical industry, (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate may serve as a key intermediate in the synthesis of other complex organic molecules or as a component in the development of new materials with specific properties.
Used in Biological Research:
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate is used as a research tool in biological studies to explore its interactions with biological systems, potentially leading to new insights into its mechanisms of action and applications in medicine or biotechnology.

Upstream product

• 121358-46-1 (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-formyl-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 123-08-0 4-hydroxy-benzaldehyde 
• 572-09-8 acetobromogalactose 
• 4163-60-4 β-D-galactose peracetate 
• 25878-60-8 D-galactose pentaacetate 

Downstream Products

• 1127247-23-7 C₂₀H₃₀N₄O₁₂S 
• 1127247-22-6 C₂₈H₃₈N₄O₁₆S 
• 1127247-21-5 C₃₃H₄₆N₄O₁₈S 
• 1127247-20-4 C₃₄H₄₃N₅O₁₈ 
• 1127247-19-1 C₃₀H₄₁N₃O₁₇ 
• 1127247-17-9 C₂₀H₂₄N₂O₈S 
• 1127247-16-8 C₂₈H₃₂N₂O₁₂S 
• 1127247-15-7 C₂₈H₃₀N₂O₁₄S 
• 1127247-14-6 CF₃O₃S^(1-)*C₂₆H₃₀N₃O₁₄⁽¹⁺⁾ 
• 1127247-05-5 C₅₇H₉₃N₃O₁₃Si₄ 

Relevant academic research and scientific papers

Real-Time Multi-Photon Tracking and Bioimaging of Glycosylated Theranostic Prodrugs upon Specific Enzyme Triggered Release

Real-time tracking of prodrug uptake, delivery and activation in vivo represents a major challenge for prodrug development. Herein, we demonstrate the use of novel glycosylated theranostics of the cancer pharmacophore Amonafide in highly-selective, enzyma

BIO-ACTIVATED REPORTERS TO VISUALIZE, IN REAL TIME, SPECIFIC GENE THERAPY PRODUCTS

Provided herein are MRI contrast agents that are conditionally activated by an enzyme from a reporter gene coupled to a gene of interest. In some embodiments, provided herein is a platform where a substrate (blocking access of water to a Gd(III) ion) is r

Anticancer theranostic compound having colorectal cancer specificity

The present invention relates to a colorectal cancer selective anti-cancer therapeutic agent containing comprising a compound represented by chemical formula 1. The present invention may present a novel approach to the development of a wide range of small

COMPOSITION AND METHODS FOR IMAGING CELLS

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

Self-Immolative Activation of β-Galactosidase-Responsive Probes for In Vivo MR Imaging in Mouse Models

Our lab has developed a new series of self-immolative MR agents for the rapid detection of enzyme activity in mouse models expressing β-galactosidase (β-gal). We investigated two molecular architectures to create agents that detect β-gal activity by modul

FLUOROGENIC GLYCOSIDASE SUBSTRATE AND ASSOCIATED DETECTION METHOD

The invention relates to novel glycosidase substrates of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R′9, V, X, Y and Z are as defined in claim 1, and a method for detecting the presence of a catalytically active glycosidase by means of one of said substrates.

ANTI-EGFR ANTIBODY DRUG CONJUGATES

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.

ENZYME-DIRECTED IMMUNOSTIMULANT AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATION(S)

The disclosed invention relates to the novel composition of matter that allows for the controlled release of highly active compounds to be delivered to a desired site. This novel composition utilizes the immune system to allow for the controlled release of desired compounds. The present invention can utilize a plurality of highly active compounds, with one embodiment being the use of chemotherapeutics for the treatment of cancer.

ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy

Herein we report the synthesis and activity of an enzyme-directed immunostimulant with immune cell activation mediated by β-galactosidase, either exogenously added, or on B16 melanoma cells. Covalent attachment of a β-galactopyranoside to an imidazoquinoline immunostimulant at a position critical for activity resulted in a pro-immunostimulant that could be selectively converted by β-galactosidase into an active immunostimulant. The pro-immunostimulant exhibited β-galactosidase-directed immune cell activation as measured by NF-κB transcription in RAW-Blue macrophages or cytokine production (TNF, IL-6, IL-12) in JAWSII monocytes. Conversion of the pro-immunostimulant into an active immunostimulant was also found to occur using β-galactosidase-enriched B16 melanoma cells. In co-culture experiments with either immune cell line, β-galactosidase-enriched B16 cells effected activation of bystander immune cells.